{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:17:03Z","timestamp":1777580223573,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.breast.2022.10.009","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T05:53:19Z","timestamp":1666072399000},"page":"236-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Real-world study of patients with germline BRCA1\/2-mutated human epidermal growth factor receptor 2\u2012Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel"],"prefix":"10.1016","volume":"66","author":[{"given":"Reshma","family":"Mahtani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Niyazov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhakti","family":"Arondekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Rider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Massey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Patrick","family":"Lux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.breast.2022.10.009_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.breast.2022.10.009_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3747\/co.22.2359","article-title":"A population-based study of ethnicity and breast cancer stage at diagnosis in Ontario","volume":"22","author":"Ginsburg","year":"2015","journal-title":"Curr Oncol"},{"key":"10.1016\/j.breast.2022.10.009_bib3","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s12885-015-1497-1","article-title":"Primary care characteristics and stage of cancer at diagnosis using data from the national cancer registration service, quality outcomes framework and general practice information","volume":"15","author":"Maclean","year":"2015","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.breast.2022.10.009_bib4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/1758834015608993","article-title":"Optimal management of hormone receptor positive metastatic breast cancer in 2016","volume":"7","author":"Reinert","year":"2015","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"10.1016\/j.breast.2022.10.009_bib5","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/bjc.2013.6","article-title":"Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study","volume":"108","author":"Walters","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2022.10.009_bib6","series-title":"AJCC cancer staging manual","first-page":"58","article-title":"Breast","author":"Hortobagyi","year":"2017"},{"key":"10.1016\/j.breast.2022.10.009_bib7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1200\/EDBK_201313","article-title":"New and important changes in the TNM staging system for breast cancer","volume":"38","author":"Hortobagyi","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"10.1016\/j.breast.2022.10.009_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/jclinpath-2014-202571","article-title":"Updated UK recommendations for HER2 assessment in breast cancer","volume":"68","author":"Rakha","year":"2015","journal-title":"J Clin Pathol"},{"issue":"31","key":"10.1016\/j.breast.2022.10.009_bib9","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2022.10.009_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264637","article-title":"Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics","volume":"17","author":"Nelson","year":"2022","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.breast.2022.10.009_bib11","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"5645","key":"10.1016\/j.breast.2022.10.009_bib12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.breast.2022.10.009_bib13","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/jnci\/91.11.943","article-title":"Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer","volume":"91","author":"Peto","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"4_Supplement","key":"10.1016\/j.breast.2022.10.009_bib14","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS18-GS2-01","article-title":"Age-related breast cancer risk estimates for the general population based on sequencing of cancer predisposition genes in 19,228 breast cancer patients and 20,211 matched unaffected controls from US based cohorts in the CARRIERS study","volume":"79","author":"Couch","year":"2019","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.breast.2022.10.009_bib15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.2007.55-a","article-title":"Variation of breast cancer risk among BRCA1\/2 carriers","volume":"299","author":"Begg","year":"2008","journal-title":"JAMA"},{"issue":"39","key":"10.1016\/j.breast.2022.10.009_bib16","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.1073\/pnas.1415979111","article-title":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","volume":"111","author":"Gabai-Kapara","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"10.1016\/j.breast.2022.10.009_bib17","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.breast.2022.10.009_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000516420","article-title":"AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2021","volume":"16","author":"Thill","year":"2021","journal-title":"Breast Care"},{"issue":"12","key":"10.1016\/j.breast.2022.10.009_bib19","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2022.10.009_bib20","article-title":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancer V.4.2022","year":"2022","journal-title":"\u00a9 National Comprehensive Cancer Network, Inc."},{"issue":"6","key":"10.1016\/j.breast.2022.10.009_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2022.10.009_bib22","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2022.10.009_bib23","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.breast.2022.10.009_bib24","doi-asserted-by":"crossref","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","article-title":"Breast cancer, version 3.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Gradishar","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"issue":"4","key":"10.1016\/j.breast.2022.10.009_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000361","article-title":"Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis","volume":"3","author":"Poggio","year":"2018","journal-title":"ESMO Open"},{"issue":"4 Supplement","key":"10.1016\/j.breast.2022.10.009_bib26","article-title":"EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation","volume":"78","author":"Litton","year":"2018","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.breast.2022.10.009_bib27","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jama.2018.10136","article-title":"Real-world evidence and real-world data for evaluating drug safety and effectiveness","volume":"320","author":"Corrigan-Curay","year":"2018","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.breast.2022.10.009_bib28","doi-asserted-by":"crossref","first-page":"djx187","DOI":"10.1093\/jnci\/djx187","article-title":"Real-world data for clinical evidence generation in oncology","volume":"109","author":"Khozin","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.breast.2022.10.009_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021864","article-title":"EU-funded initiatives for real world evidence: descriptive analysis of their characteristics and relevance for regulatory decision-making","volume":"8","author":"Plueschke","year":"2018","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.breast.2022.10.009_bib30","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.breast.2022.10.009_bib31","series-title":"EphMRA code of conduct","year":"2019"},{"key":"10.1016\/j.breast.2022.10.009_bib33","author":"Office for Civil Rights"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977622001746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977622001746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:47:20Z","timestamp":1760777240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977622001746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":32,"alternative-id":["S0960977622001746"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2022.10.009","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world study of patients with germline BRCA1\/2-mutated human epidermal growth factor receptor 2\u2012Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2022.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Pfizer and The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}